164 related articles for article (PubMed ID: 37347766)
1. Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Medicare Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity.
Pockros B; Shabet C; Stensland K; Herrel L
Urol Pract; 2023 Sep; 10(5):467-475. PubMed ID: 37347766
[TBL] [Abstract][Full Text] [Related]
2. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
[TBL] [Abstract][Full Text] [Related]
4. Online Tools to Decrease Out-of-Pocket Prescription Costs for Patients: A Practical Guide for Urologists.
Pockros B; Cortese BD; Michel K; Ellis TA; Talwar R
Urol Pract; 2024 May; 11(3):454-460. PubMed ID: 38640418
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
[TBL] [Abstract][Full Text] [Related]
6. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV
JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783
[TBL] [Abstract][Full Text] [Related]
7. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
9. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
10. The role of satisfaction and switching costs in Medicare Part D choices.
Han J; Ko DW; Urmie JM
Res Social Adm Pharm; 2014; 10(2):398-407. PubMed ID: 23988694
[TBL] [Abstract][Full Text] [Related]
11. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
12. Cost-Savings and Patient Experience with a Pharmacy-Led Medicare Part D Consultation Service.
Murry L; Gerleman B; Deng H; Urmie J
Innov Pharm; 2020; 11(2):. PubMed ID: 34007601
[TBL] [Abstract][Full Text] [Related]
13. Impact of an open enrollment service on costs for Medicare Part D beneficiaries.
Leonard CE; Cohenour FV; DeLoach LA; Galdo JA
J Am Pharm Assoc (2003); 2017; 57(3S):S225-S228. PubMed ID: 28412055
[TBL] [Abstract][Full Text] [Related]
14. Simplifying The Medicare Plan Finder Tool Could Help Older Adults Choose Lower-Cost Part D Plans.
McGarry BE; Maestas N; Grabowski DC
Health Aff (Millwood); 2018 Aug; 37(8):1290-1297. PubMed ID: 30080456
[TBL] [Abstract][Full Text] [Related]
15. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
16. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Potential Urologic Prescription Drug Savings With Mark Cuban Cost Plus Drug Company.
Schloegel V; Harris L; Harris A; Dropkin B
Urol Pract; 2024 Mar; 11(2):276-282. PubMed ID: 38377158
[TBL] [Abstract][Full Text] [Related]
19. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
20. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
